Studying new tests to detect colon cancer early in people at high risk
Studies new low-cost tests for colon cancer detection in high-risk adults across Europe.
Plain-language title generated from the registry record
Registry title: Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
Key facts
- Where
- Lübeck and Mainz-GE, GermanySee the 2 sites
Where in Germany
- MKI UKSH LübeckLübeck, GermanyTaking people
- UMC Mainz: University Medical Center MainzMainz-GE, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Firalis SA
- Trial code
- NCT06515821
- Record updated
- 16 September 2026
- Original description
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.Read full original descriptionShow less
Multicentre Observational Study for the Data Collection, Development and Evaluation of the Performance of Novel CRC Screening and Diagnostic Methods ONCOSCREEN-CS
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.
Inclusion: CRC Group; Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study; Subjects aged ≥18 years; Subject is willing to undergo FOBT test, colonoscopy, and tissue biopsy; Subject for whom the decision to perform a colonoscopy has been made by the treating physician; Subject has positive CRC diagnosis according to colonoscopy result; Covered by a Health Insurance System; Subject is able to comply with all study procedures; Control Group with risks and presence of polyps; Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study; Subjects aged ≥18 years; Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia; Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy; Subject has negative CRC diagnosis according to colonoscopy result; Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness; Control Group with risks and absence of polyps; Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study; Subjects aged ≥18 years; Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia; Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy; Subject has negative CRC diagnosis according to colonoscopy result; Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness; Control Group with no risks; Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study; Subjects aged ≥40 years; Otherwise healthy individuals without any recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidemia; Subject be willing to undergo FOBT test; Subject has negative FOBT result.
Exclusion: For the CRC Group; Legal incapacity or limited legal capacity; Subject did not sign the Informed Consent form; Subject who, according to the investigator's assessment, presents with an unstable medical condition contraindicating the performance of the planned blood test, stool test or breath test; Subject has had surgery in the previous 6-8 weeks or is under medication for CRC treatment; For the control groups; Legal incapacity or limited legal capacity; Subject did not sign the Informed Consent form; Previous history of any type of cancer; Gastrointestinal disorders or other serious acute or chronic diseases.